MEK inhibitor–based genomically matched combinatorial targeted therapies in metastatic pancreatic adenocarcinoma with KRAS alterations
The Oncologist · 2026
DOI: 10.1093/oncolo/oyag040 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift The Oncologist, 2026. Verfasst von Elizabeth D Auckley und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Medical College of Wisconsin, Milwaukee, WI 53226, United States. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Pancreatic Ductal, Pancreatic Neoplasms, Protein Kinase Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCATS NIH HHS.
Abstract (Originalsprache)
Introduction
Pancreatic ductal adenocarcinoma (PDAC) is often caused by mutations in multiple genes, including KRAS (activating the Ras-Raf-MEK-ERK pathway). This study evaluated the role of MEK inhibitor (MEKi)–based combinatorial targeted therapies in patients with PDAC.
Methods
This is a retrospective/prospective observational, single-institution study, including 29 patients with metastatic PDAC with KRAS alterations, treated with MEKi therapies between 2022 and 2024.
Results
Ten patients had KRAS G12R (34.5%), ten G12D (34.5%), and nine G12V (31%). The majority of patients received MEKi therapy as third-line and beyond (KRAS G12R/G12D/G12V: 60%/50%/78%, respectively). Median overall survival from MEKi initiation for KRAS G12R/G12D/G12V was 8.2/5.1/4.7 months (P = .5), respectively, and median progression-free survival was 4.4/2.3/1.4 months (P = .11). Six (21%) patients discontinued at least one drug in the treatment combination due to toxicity.
Conclusions
MEKi–based combinatorial therapies had modest disease control in patients with KRAS G12R, and minimal disease control in patients with KRAS G12D/V in the late-line setting.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Medical College of Wisconsin, Milwaukee, WI 53226, United States.
- Department of Medicine, Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI 53226, United States.
- Data Science Institute, Division of Biostatistics, Medical College of Wisconsin, Milwaukee, WI 53226, United States.
- Department of Pharmacy, Froedtert Health, Milwaukee, WI 53226, United States.
- Department of Surgery, Medical College of Wisconsin and the LaBahn Pancreatic Cancer Program, Milwaukee, WI 53226, United States.
- Department of Biochemistry, Medical College of Wisconsin and the LaBahn Pancreatic Cancer Program, Milwaukee, WI 53226, United States.
ORCID-Profile: Elizabeth D Auckley, Aniko Szabo, Mohammed Aldakkak, Samih Z Thalji, Thomas McFall, Razelle Kurzrock
Förderung
- NCATS NIH HHS
Zitieren
APA
Auckley, E. D., Yohay, S., Ying, G., Szabo, A., Wittmann, J., Grahl, J., Aldakkak, M., Thalji, S. Z., McFall, T., Kurzrock, R., George, B., & Kamgar, M. (2026). MEK inhibitor–based genomically matched combinatorial targeted therapies in metastatic pancreatic adenocarcinoma with KRAS alterations. The Oncologist. https://doi.org/10.1093/oncolo/oyag040
Vancouver
Auckley ED, Yohay S, Ying G, Szabo A, Wittmann J, Grahl J, et al. MEK inhibitor–based genomically matched combinatorial targeted therapies in metastatic pancreatic adenocarcinoma with KRAS alterations. The Oncologist. 2026. doi:10.1093/oncolo/oyag040
BibTeX
@article{Auckley2026,
author = {Auckley, Elizabeth D and Yohay, Stephanie and Ying, Grace and Szabo, Aniko and Wittmann, Jacquelyn and Grahl, Justin and Aldakkak, Mohammed and Thalji, Samih Z and McFall, Thomas and Kurzrock, Razelle and George, Ben and Kamgar, Mandana},
title = {MEK inhibitor–based genomically matched combinatorial targeted therapies in metastatic pancreatic adenocarcinoma with KRAS alterations},
journal = {The Oncologist},
year = {2026},
doi = {10.1093/oncolo/oyag040}
}
EUVIMED